Alzaid M, Al-Naseem A, Al-Niaimi F, Ali F R
University of Manchester Medical School, Manchester, UK.
Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark.
Clin Exp Dermatol. 2022 May;47(5):819-832. doi: 10.1111/ced.15021. Epub 2022 Jan 13.
Timolol, a nonselective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome.
噻吗洛尔是一种非选择性β-肾上腺素能受体阻滞剂，耐受性良好，在皮肤科越来越受欢迎，尤其是在婴儿血管瘤（IH）的治疗中。其作用主要归因于血管收缩、抑制血管生成以及促进角质形成细胞迁移以实现再上皮化和伤口愈合。我们综述了噻吗洛尔在几种皮肤病中的应用证据，包括婴儿血管瘤、化脓性肉芽肿、卡波西肉瘤、慢性伤口愈合、术后伤口、寻常痤疮、玫瑰痤疮、湿疹和红阴囊综合征。
